FIELD: medicine.
SUBSTANCE: invention relates to a compound of the general formula I or its stereoisomer, in which R1 is selected from hydrogen and unsubstituted C1-C6 alkyl; R2 and R3, each independently, is selected from hydrogen and -C(=O)Ra; R4 is selected from hydrogen and -C(=O)Ra; Ra is unsubstituted C1-C6 alkyl. The invention also relates to a method for the production of a compound of the formula I by cultivation of PHM005 strain of wild-type marine bacteria under corresponding conditions, as well as to a pharmaceutical composition based on it.
EFFECT: new compounds and a pharmaceutical composition based on them are obtained, which can be used in medicine for the treatment of malignant neoplasm selected from lung cancer, colon cancer, breast cancer and pancreatic cancer.
16 cl, 10 dwg, 2 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VERSIONS OF POLYPEPTIDES SPLITTING FUSARIOTOXINS CONTAINING THEIR ADDITIVE, THEIR USE AND A METHOD FOR SPLITTING FUSARIOTOXINS | 2015 |
|
RU2720517C2 |
| NOVEL FUSION PROTEINS SPECIFIC FOR CD137 AND GPC3 | 2020 |
|
RU2814653C2 |
| METHOD FOR REMOVAL OF RESINOUS SUBSTANCES FROM VEGETABLE OIL AND ITS REFINING | 2018 |
|
RU2772452C2 |
| DISPLAY OF AN INTEGRAL MEMBRANE PROTEIN ON EXTRACELLULAR ENVELOPED POXVIRUS VIRIONS | 2017 |
|
RU2759846C2 |
| CONJUGATE OF ANTI-CLAUDIN ANTIBODY AND MEDICINAL AGENT AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2826119C1 |
| BISPECIFIC 2+1 ANTIBODIES | 2018 |
|
RU2797305C2 |
| SCREENING OF ATTACHMENT SITES WITH FIXED POINT IN CYSTEINE-MODIFIED ANTIBODY-TOXIN (TDC) CONJUGATE | 2018 |
|
RU2816510C2 |
| COMBINATION OF ANTIBODY AGAINST HGFR AND HEGFR FOR TREATMENT OF TUMOR AND/OR METASTASIS | 2019 |
|
RU2788606C2 |
| ANTI-CD39 ANTIBODIES, COMPOSITIONS CONTAINING ANTI-CD39 ANTIBODIES AND METHODS OF APPLICATION OF ANTI-CD39 ANTIBODIES | 2018 |
|
RU2795348C2 |
| CHIMERIC ANTIGEN RECEPTORS | 2015 |
|
RU2745705C2 |
